>Marché nord-américain du dépistage de la santé, par type de test (tests de cholestérol, test du diabète , dépistage du cancer, test de contrôle général, MST, test de tension artérielle et autres), type d'emballage (dépistage de la santé de base, profil des personnes âgées, bilan de santé des femmes, bilan de santé des hommes, bilan cardiaque , bilan du diabète et autres), type de panel (panels multi-tests et panels à test unique), type d'échantillon (sang, urine, sérum , salive et autres), technologie (immuno-essais, imagerie médicale, QPCR (réaction en chaîne par polymérase quantitative), Q-FISH (fluorescence quantitative, hybridation in situ), TRF (fragment de restriction terminale), STELA (analyse de la longueur d'un seul télomère) et autres), état (maladie cardiovasculaire, troubles métaboliques, cancer, affections inflammatoires, troubles musculo-squelettiques, affections neurologiques, complications de l'hépatite C, affections liées à l'immunologie et Autres), sites de collecte d'échantillons (hôpitaux, domiciles, laboratoires de diagnostic, bureaux et autres), canal de distribution (appels d'offres directs, ventes au détail et autres), pays (États-Unis, Canada et Mexique), tendances et prévisions de l'industrie jusqu'en 2028.
Analyse et perspectives du marché : marché nord-américain du dépistage médical
Le marché nord-américain du dépistage de santé devrait connaître une croissance du marché au cours de la période de prévision de 2021 à 2028. Data Bridge Market Research analyse que le marché croît avec un TCAC de 12,1 % au cours de la période de prévision de 2021 à 2028 et devrait atteindre 2,85 millions USD d'ici 2028. Le nombre croissant de maladies chroniques, la population gériatrique et la sensibilisation croissante à la détection et au traitement précoces des maladies sont les principaux moteurs qui ont propulsé la demande du marché au cours de la période de prévision.
Le dépistage médical est une méthode importante de détection précoce d'un trouble spécifique. Les tests de dépistage sont souvent utilisés en médecine préventive pour identifier si un individu présente des signes précoces de facteurs de risque d'une maladie. Les maladies qui peuvent être détectées par dépistage comprennent le cancer, le diabète, l'hypercholestérolémie, l'hypertension artérielle et l'ostéoporose. L'augmentation du volume des maladies chroniques, la population gériatrique et la sensibilisation croissante à la détection et au traitement précoces des maladies propulsent la croissance du marché du dépistage médical.
La sensibilisation croissante des citoyens à la détection et au traitement précoces des maladies et l'augmentation des dépenses de santé accroissent la demande de dépistage médical et agissent comme des moteurs du marché.
La demande croissante de dépistages médicaux en raison de leur efficacité, le nombre croissant de prestataires de services et la campagne de sensibilisation croissante des acteurs privés et publics en matière de dépistage médical stimulent la croissance du marché des dépistages médicaux au cours de la période de prévision et constituent une opportunité. Cependant, le coût élevé des tests de dépistage pourrait entraver la croissance du marché au cours de la période de prévision.
North America health screening market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief; our team will help you create a revenue impact solution to achieve your desired goal.
North America Health Screening Market Scope and Market Size
North America health screening market is segmented on the basis of eight notable segments, test type, package type, panel type, sample type, technology, condition, sample collection sites, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of test type, the North America health screening market is segmented into cholesterol tests, diabetes test, cancer screening, general checkup test, STDs, blood pressure test, and others. In 2021, cholesterol test segment is expected to dominate the market because of increasing prevalence of the cholesterol related disorder and improper dietary habits which increases the risk of these test.
- On the basis of package type, the North America health screening market is segmented into basic health screening, senior citizen profile, women health check, men health check, heart check, diabetes check, and others. In 2021, basic health screening segment is expected to dominate the market because of increasing competition in the market due to which different labs are given packages to attract the patient to undergo screening under their laboratory.
- On the basis of panel type, North America health screening market is segmented into multi-test panels and single-test panels. In 2021, multi-test panels segment is expected to dominate the market as various laboratories and diagnostic centers use multi-test panels to screen and in current scenario the diseases are interconnected by symptoms, occurrence which increase the use of multi-panel to screen different test at same time
- On the basis of sample type, the North America health screening market is segmented into blood, urine, serum, saliva, and others. In 2021, blood segment is expected to dominate the market as it is the easiest and most convenient method for screening and diagnosis.
- Sur la base de la technologie, le marché nord-américain du dépistage médical est segmenté en immuno-essais, imagerie médicale, QPCR (Quantitative Polymerase Chain Reaction), Q-FISH (Quantitative Fluorescence, hybridation in situ), TRF (Terminal Restriction Fragment), STELA (Single Telomere Length Analysis), et autres. En 2021, le segment des immuno-essais devrait dominer le marché car les immuno-essais contribuent à diverses applications, notamment les transfusions sanguines, les thérapies géniques, les opérations d'implantation, le dépistage des maladies infectieuses et autres. Les États-Unis et le Canada sont le principal marché des nouvelles technologies et croient en l'avancement de la technologie existante, ce qui est également un facteur majeur de croissance du segment.
- Sur la base des conditions, le marché nord-américain du dépistage médical est segmenté en maladies cardiovasculaires, troubles métaboliques, cancer, maladies inflammatoires, troubles musculo-squelettiques, maladies neurologiques, complications de l'hépatite C, maladies liées à l'immunologie et autres. En 2021, la prévalence du segment des maladies cardiovasculaires en Amérique du Nord est élevée, car près de 3 % des personnes souffrent de crises cardiaques nouvelles ou récurrentes, ce qui permet à ce segment de croître au cours de la période de prévision.
- Sur la base des sites de collecte d'échantillons, le marché nord-américain du dépistage médical est segmenté en hôpitaux, maisons, laboratoires de diagnostic, bureaux et autres. En 2021, le segment des hôpitaux devrait dominer le marché, car les hôpitaux disposent de toutes les installations nécessaires pour diagnostiquer et traiter les troubles.
- En fonction du canal de distribution, le marché nord-américain du dépistage médical est segmenté en appels d'offres directs, ventes au détail et autres. En 2021, le segment des appels d'offres directs devrait dominer le marché en raison de l'augmentation des ventes globales de programmes de dépistage médical.
Analyse du marché du dépistage médical en Amérique du Nord au niveau des pays
Le marché nord-américain du dépistage médical est analysé et des informations sur la taille du marché sont fournies sur le type de test, le type d'emballage, le type de panel, le type d'échantillon, la technologie, l'état, les sites de collecte d'échantillons et le canal de distribution. Les pays couverts par le rapport sur le marché nord-américain du dépistage médical sont les États-Unis, le Canada et le Mexique.
Les États-Unis, dans la région nord-américaine, devraient connaître le taux de croissance le plus élevé au cours de la période de prévision de 2021 à 2028 en raison de l'augmentation de la population gériatrique et de la sensibilisation croissante à la détection et au traitement précoces des maladies.
La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie des pays, les actes réglementaires et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques nord-américaines et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des canaux de vente sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.
Le nombre croissant de maladies chroniques, telles que le cancer, le diabète et les maladies cardiovasculaires à travers le monde et l'augmentation de la population gériatrique stimulent la croissance du marché du dépistage médical en Amérique du Nord
Le marché nord-américain du dépistage de la santé vous fournit également une analyse de marché détaillée de la croissance de chaque pays dans le secteur des produits de dépistage avec les ventes de médicaments, l'impact des progrès, de la technologie et des changements dans les scénarios réglementaires avec leur soutien au marché du dépistage de la santé. Les données sont disponibles pour la période historique de 2010 à 2019.
Analyse du paysage concurrentiel et des parts de marché du dépistage médical en Amérique du Nord
Le paysage concurrentiel du marché du dépistage médical en Amérique du Nord fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les pipelines d'essais de produits, les approbations de produits, les brevets, la largeur et l'étendue du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise liée au marché du fluorure de diamine d'argent (SDF)
Français Les principales entreprises opérant sur le marché du dépistage cardiaque en Amérique du Nord sont Quest Diagnostics Incorporated, Laboratory Corporation of America, Sonic Healthcare Limited, Exact Sciences Corporation, Healius Limited, GRAIL, Eurofins Scientific, , SYNLAB International GmbH, UNILABS, LabPLUS, BioReference Laboratories, , ACM Global Laboratories, Cerba Healthcare, Quidel Corporation, Innova Medical Group, AMEDES Holding GmbH, RadNet, Inc., Natera, Inc., Trinity Biotech, Nuffield Health, RepeatDx, NeoGenomics Laboratories, HU Group Holdings, Inc., Lifelabs, ARUP Laboratories, Q2 Solutions, Genova Diagnostics, Life Length, DNA Labs India, , Telomere Diagnostics, Charles River Laboratories, Ambry Genetics, SpectraCell Laboratories, Inc., Dr. Lal PathLabs, et entre autres.
De nombreux événements, accords et webinaires sont également initiés par des entreprises du monde entier, ce qui accélère également le marché du dépistage médical en Amérique du Nord.
Par exemple,
- En avril 2021, Ambry Genetics a annoncé qu'elle participerait à la réunion annuelle de génétique clinique 2021 de l'ACMG. Cela a donné à l'entreprise une plate-forme pour présenter ses idées commerciales.
- En septembre 2021, les laboratoires ARUP ont annoncé un partenariat avec Air Med pour fournir des installations médicales aux patients en fournissant du sang aux vols et à d'autres installations. Cela augmentera le bassin de patients pour le prestataire de services qui aidera les laboratoires au cours de la période de prévision.
La collaboration, le lancement de produits, l'expansion commerciale, les récompenses et la reconnaissance, les coentreprises et d'autres acteurs du marché améliorent le marché de l'entreprise sur le marché du dépistage de santé en Amérique du Nord, ce qui profite également à l'organisation pour améliorer son offre de médicaments de dépistage de santé.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA HEALTH SCREENING MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TEST TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 DISTRIBUTION CHANNELUSER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 REGULATIONS
5.1 WORLD HEALTH ORGANIZATION
5.2 NORTH AMERICA
5.3 EUROPE
6 INDUSTRIAL INSIGHTS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING PREVALENCE OF CHRONIC DISEASES
7.1.2 GROWING GERIATRIC POPULATION
7.1.3 GOVERNMENT INITIATIVES UNDERTAKEN TO IMPLEMENT SCREENING PROGRAMS FOR VARIOUS DISEASES
7.1.4 RISING PER CAPITA INCOME AND HEALTHCARE EXPENDITURE
7.1.5 GRWOING NUMBER OF SCREENING PROGRAMS WORLDWIDE
7.2 RESTRAINTS
7.2.1 SCRACITY OF TECHNICALLY-SKILLED PROFESSIONALS
7.2.2 RISKS ASSOCIATED WITH SCREENING
7.2.3 LACK OF ACCESSIBILITY
7.3 OPPORTUNITIES
7.3.1 TECHNOLOGICAL ADVANCEMENTS IN HEALTH SCREENING
7.3.2 ACQUSITIONS AND MERGERS AMONG THE MARKET
7.3.3 NEW PRODUCT LAUNCHES IN THE MARKET
7.4 CHALLENGES
7.4.1 HIGHER COST OF HEALTH SCREENING
7.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING SCREENING TESTS
8 COVID-19 IMPACT ON NORTH AMERICA HEALTH SCREENING MARKET
8.1 PRICE IMPACT
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISIONS FOR MANUFACTURERS
8.5 CONCLUSION
9 NORTH AMERICA HEALTH SCREENING MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 CHOLESTEROL TESTS
9.2.1 TOTAL CHOLESTEROL TESTS
9.2.2 TRIGLYCERIDES
9.2.3 LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL
9.2.4 HIGH-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL
9.3 DIABETES TEST
9.3.1 FASTING/RANDOM BLOOD SUGAR TEST
9.3.2 A1C TEST
9.3.3 GLUCOSE TOLERANCE TEST
9.4 CANCER SCREENING
9.4.1 LIQUID BIOPSY
9.4.2 MAMMOGRAMS, OSTEOPOROSIS, BREAST MRI AND PAP SMEAR TESTS
9.4.3 LOW-DOSE HELICAL COMPUTED TOMOGRAPHY
9.4.4 COLORECTAL CANCER SCREENING TEST (STOOL TESTS, SIGMOIDOSCOPY, COLONOSCOPY, BLOOD-BASED DNA TEST, DOUBLE-CONTRAST BARIUM ENEMA (DCBE), AND SINGLE-SPECIMEN GFOBT)
9.4.5 PROSTATE SPECIFIC ANTIGEN (PSA) TEST
9.4.6 NEW-EARLY DETECTION CANCER TESTS
9.4.7 ALPHA FETOPROTEIN BLOOD TEST
9.4.8 CA-125 TEST
9.4.9 OTHERS
9.5 GENERAL CHECK UP TEST
9.5.1 REGULAR CHECK UP
9.5.1.1 REGULAR BLOOD TEST
9.5.1.2 X-RAYS
9.5.1.3 ECG
9.5.1.4 FECALYSIS
9.5.1.5 URINALYSIS
9.5.1.6 BMI
9.5.1.7 OTHERS
9.5.2 EYE CHECK UP
9.5.3 DENTAL TEST
9.5.4 HEARING TEST
9.6 STD’S
9.6.1 CHLAMYDIA
9.6.2 GONORRHEA
9.6.3 HPV
9.6.4 HIV
9.6.5 OTHERS
9.7 BLOOD PRESSURE TEST
9.8 OTHERS
9.8.1 LIVER FUNCTION TESTS
9.8.2 KIDNEY PROFILE
9.8.3 OTHERS
10 NORTH AMERICA HEALTH SCREENING MARKET, BY PANEL TYPE
10.1 OVERVIEW
10.2 MULTI-TEST PANELS
10.3 SINGLE-TEST PANELS
10.3.1 INFLAMMATION TESTS
10.3.2 OXIDATIVE STRESS TESTS
10.3.3 HEAVY METAL TESTS
10.3.4 TELOMERE
11 NORTH AMERICA HEALTH SCREENING MARKET, BY PACKAGE TYPE
11.1 OVERVIEW
11.2 BASIC HEALTH SCREENING
11.3 SENIOR CITIZEN PROFILE
11.4 WOMEN HEALTH CHECK
11.5 MEN HEALTH CHECK
11.6 HEART CHECK
11.7 DIABETES CHECK
11.8 OTHERS
12 NORTH AMERICA HEALTH SCREENING MARKET, BY SAMPLE TYPE
12.1 OVERVIEW
12.2 BLOOD
12.3 URINE
12.4 SERUM
12.5 SALIVA
12.6 OTHERS
13 HEALTH SCREENING MARKET, BY TECHNOLOGY
13.1 OVERVIEW
13.2 IMMUNOASSAYS
13.3 MEDICAL IMAGING
13.4 QPCR
13.4.1 MMQPCR (MONOCHROME MULTIPLEX QPCR)
13.4.2 ATLQPCR (ABSOLUTE TELOMERE LENGTH QPCR)
13.5 Q-FISH
13.5.1 PRINS (PRIMED IN SITU SUBTYPE OF Q-FISH)
13.5.2 FLOW-FISH
13.5.3 HT Q-FISH (HIGH THROUGHPUT Q-FISH)
13.6 TRF (TERMINAL RESTRICTION FRAGMENT)
13.7 STELA (SINGLE TELOMERE LENGTH ANALYSIS)
13.8 OTHERS
14 NORTH AMERICA HEALTH SCREENING MARKET, BY CONDITION
14.1 OVERVIEW
14.2 CARDIOVASCULAR DISEASE
14.2.1 CORONARY HEART DISEASE
14.2.2 ATHEROSCLEROSIS
14.3 METABOLIC DISORDERS
14.3.1 DIABETES MELLITUS
14.3.2 OBESITY
14.4 CANCER
14.5 INFLAMMATORY CONDITIONS
14.5.1 AUTOIMMUNE CONDITIONS
14.5.2 ALLERGIES
14.5.3 ARTHRITIS
14.5.4 ASTHMA
14.5.5 INFLAMMATORY DIGESTIVE PROBLEMS
14.6 MUSCULOSKELETAL DISORDERS
14.6.1 OSTEOPOROSIS
14.6.2 RHEUMATOID ARTHRITIS
14.7 NEUROLOGICAL CONDITIONS
14.7.1 CHRONIC STRESS
14.7.2 ALZHEIMER'S DISEASE
14.8 IMMUNOLOGY-RELATED CONDITIONS
14.9 HEPATITIS C COMPLICATIONS
14.1 OTHERS
15 HEALTH SCREENING MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDERS
15.3 RETAIL SALES
15.4 OTHERS
16 NORTH AMERICA HEALTH SCREENING MARKET, BY SAMPLE COLLECTION SITES
16.1 OVERVIEW
16.2 HOSPITAL
16.2.1 ACUTE CARE HOSPITALS
16.2.2 LONG-TERM CARE HOSPITALS
16.2.3 NURSING FACILITIES
16.2.4 REHABILITATION CENTERS
16.3 HOME
16.4 DIAGNOSTIC LABORATORIES
16.5 OFFICES
16.6 OTHERS
17 NORTH AMERICA HEALTH SCREENING MARKET, BY REGION
17.1 NORTH AMERICA
17.1.1 U.S.
17.1.2 CANADA
17.1.3 MEXICO
18 NORTH AMERICA HEALTH SCREENING MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 QUEST DIAGNOSTICS INCORPORATED
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.2 SONIC HEALTHCARE LIMITED
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENTS
20.3 LABORATORY CORPORATION OF AMERICA
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENT
20.4 EUROFINS SCIENTIFIC
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENTS
20.5 EXACT SCIENCES CORPORATION
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENTS
20.6 ACM NORTH AMERICA LABORATORIES
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENT
20.7 AMEDES
20.7.1 COMPANY SNAPSHOT
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENT
20.8 AMBRY GENETICS
20.8.1 COMPANY SNAPSHOT
20.8.2 SERVICE PORTFOLIO
20.8.3 RECENT DEVELOPMENTS
20.9 ARUP LABORATORIES
20.9.1 COMPANY SNAPSHOT
20.9.2 PRODUCT PORTFOLIO
20.9.3 RECENT DEVELOPMENTS
20.1 BIOREFRENCE LABORATORIES
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE ANALYSIS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT DEVELOPMENTS
20.11 CHARLES RIVER
20.11.1 COMPANY SNAPSHOT
20.11.2 REVENUE ANALYSIS
20.11.3 PRODUCT PORTFOLIO
20.11.4 RECENT DEVELOPMENTS
20.12 CERBA HEALTHCARE
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENT
20.13 DNA LABS INDIA
20.13.1 COMPANY SNAPSHOT
20.13.2 SERVICE PORTFOLIO
20.13.3 RECENT DEVELOPMENT
20.14 DR LAL PATH LABS
20.14.1 COMPANY SNAPSHOT
20.14.2 REVENUE ANALYSIS
20.14.3 PRODUCT PORTFOLIO
20.14.4 RECENT DEVELOPMENT
20.15 GENOVA DIGNOSTICS
20.15.1 COMPANY SNAPSHOT
20.15.2 SERVICE PORTFOLIO
20.15.3 RECENT DEVELOPMENT
20.16 GRAIL
20.16.1 COMPANY SNAPSHOT
20.16.2 SERVICE PORTFOLIO
20.16.3 RECENT DEVELOPMENTS
20.17 HEALIUS LIMITED
20.17.1 COMPANY SNAPSHOT
20.17.2 REVENUE ANALYSIS
20.17.3 PRODUCT PORTFOLIO
20.17.4 RECENT DEVELOPMENTS
20.18 H.U. GROUP HOLDINGS, INC.
20.18.1 COMPANY SNAPSHOT
20.18.2 REVENUE ANALYSIS
20.18.3 PRODUCT PORTFOLIO
20.18.4 RECENT DEVELOPMENTS
20.19 INNOVA MEDICAL GROUP
20.19.1 COMPANY SNAPSHOT
20.19.2 PRODUCT PORTFOLIO
20.19.3 RECENT DEVELOPMENT
20.2 LABPLUS
20.20.1 COMPANY SNAPSHOT
20.20.2 PRODUCT PORTFOLIO
20.20.3 RECENT DEVELOPMENT
20.21 LIFELABS
20.21.1 COMPANY SNAPSHOT
20.21.2 SERVICE PORTFOLIO
20.21.3 RECENT DEVELOPMENTS
20.22 LIFE LENGTH
20.22.1 COMPANY SNAPSHOT
20.22.2 SERVICE PORTFOLIO
20.22.3 RECENT DEVELOPMENT
20.23 NATERA, INC.
20.23.1 COMPANY SNAPSHOT
20.23.2 REVENUE ANALYSIS
20.23.3 PRODUCT PORTFOLIO
20.23.4 RECENT DEVELOPMENTS
20.24 NEOGENOMICS LABORATORIES
20.24.1 COMPANY SNAPSHOT
20.24.2 REVENUE ANALYSIS
20.24.3 PRODUCT PORTFOLIO
20.24.4 RECENT DEVELOPMENTS
20.25 NUFFIELD HEALTH
20.25.1 COMPANY SNAPSHOT
20.25.2 PRODUCT PORTFOLIO
20.25.3 RECENT DEVELOPMENT
20.26 Q2 SOLUTIONS
20.26.1 COMPANY SNAPSHOT
20.26.2 SERVICE PORTFOLIO
20.26.3 RECENT DEVELOPMENTS
20.27 QUIDEL CORPORATION
20.27.1 COMPANY SNAPSHOT
20.27.2 REVENUE ANALYSIS
20.27.3 PRODUCT PORTFOLIO
20.27.4 RECENT DEVELOPMENTS
20.28 REPEATDX
20.28.1 COMPANY SNAPSHOT
20.28.2 PRODUCT PORTFOLIO
20.28.3 RECENT DEVELOPMENT
20.29 SONIC HEALTHCARE LIMITED
20.29.1 COMPANY SNAPSHOT
20.29.2 REVENUE ANALYSIS
20.29.3 PRODUCT PORTFOLIO
20.29.4 RECENT DEVELOPMENTS
20.3 SPECTRACELL LABORATORIES, INC.
20.30.1 COMPANY SNAPSHOT
20.30.2 SERVICE PORTFOLIO
20.30.3 RECENT DEVELOPMENT
20.31 SYNLAB INTERNATIONAL GMBH
20.31.1 COMPANY SNAPSHOT
20.31.2 PRODUCT PORTFOLIO
20.31.3 RECENT DEVELOPMENT
20.32 TELOMERE DIAGNOSTICS
20.32.1 COMPANY SNAPSHOT
20.32.2 SERVICE PORTFOLIO
20.32.3 RECENT DEVELOPMENT
20.33 TRINITY BIOTECH
20.33.1 COMPANY SNAPSHOT
20.33.2 REVENUE ANALYSIS
20.33.3 PRODUCT PORTFOLIO
20.33.4 RECENT DEVELOPMENT
20.34 UNILABS
20.34.1 COMPANY SNAPSHOT
20.34.2 PRODUCT PORTFOLIO
20.34.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
Liste des tableaux
TABLE 1 NUMBER OF PEOPLE WITH DIABETES AMONG 20–79 YEARS OLD (IN MILLION)
TABLE 2 NEW CANCER CASES FOR AGE 85+ IN U.S.
TABLE 3 ACCORDING TO THE UNITED NATIONS, IN 2019, THE TOTAL POPULATION OF AGED PEOPLE ABOVE 65 WAS 703 MILLION AND IS EXPECTED TO REACH 1.5 BILLION BY 2050.
TABLE 4 PER CAPITA AMOUNTS: THE UNITED STATES (1960–2017)
TABLE 5 NORTH AMERICA HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA CHOLESTEROL TESTS IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA CHOLESTEROL TESTS IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA DIABETES TEST IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA DIABETES TEST IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA CANCER SCREENING IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA CANCER SCREENING IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA GENERAL CHECK UP TEST IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA GENERAL CHECK UP TEST IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA REGULAR CHECK UP IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA STD’S IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA STD’S IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA BLOOD PRESSURE TEST IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA OTHERS IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA OTHERS IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA HEALTH SCREENING MARKET, BY PANEL TYPE, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA MULTI-TEST PANELS IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA SINGLE-TEST PANELS IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA SINGLE-TEST PANELS IN HEALTH SCREENING MARKET, BY PANEL TYPE, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA HEALTH SCREENING MARKET, BY PACKAGE TYPE, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA BASIC HEALTH SCREENING IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA SENIOR CITIZEN PROFILE IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA WOMEN HEALTH CHECK IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA MEN HEALTH CHECK IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA HEART CHECK IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA DIABETES CHECK IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA OTHERS IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICA HEALTH SCREENING MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA BLOOD IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA URINE IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 NORTH AMERICA SERUM IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA SALIVA IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 NORTH AMERICA OTHERS IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 NORTH AMERICA HEALTH SCREENING MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA IMMUNOASSAYS IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 NORTH AMERICA MEDICAL IMAGING IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 NORTH AMERICA QPCR IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 NORTH AMERICA QPCR IN HEALTH SCREENING MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 43 NORTH AMERICA Q-FISH IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 NORTH AMERICA Q-FISH IN HEALTH SCREENING MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 45 NORTH AMERICA TRF (TERMINAL RESTRICTION FRAGMENT) IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 NORTH AMERICA STELA (SINGLE TELOMERE LENGTH ANALYSIS) IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 NORTH AMERICA OTHERS IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 NORTH AMERICA HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 49 NORTH AMERICA CARDIOVASCULAR DISEASE IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 50 NORTH AMERICA CARDIOVASCULAR DISEASE IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA METABOLIC DISORDERS IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 52 NORTH AMERICA METABOLIC DISORDERS IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 53 NORTH AMERICA CANCER IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 54 NORTH AMERICA INFLAMMATORY CONDITIONS IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA INFLAMMATORY CONDITIONS IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 56 NORTH AMERICA MUSCULOSKELETAL DISORDERS IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 57 NORTH AMERICA MUSCULOSKELETAL DISORDERS IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 58 NORTH AMERICA NEUROLOGICAL CONDITIONS IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 59 NORTH AMERICA NEUROLOGICAL CONDITIONS IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 60 NORTH AMERICA IMMUNOLOGY-RELATED CONDITIONS IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 61 NORTH AMERICA HEPATITIS-C COMPLICATIONS IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 62 NORTH AMERICA OTHERS IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 63 NORTH AMERICA HEALTH SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 64 NORTH AMERICA DIRECT TENDERS IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 65 NORTH AMERICA RETAIL SALES IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 66 NORTH AMERICA OTHERS IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 67 NORTH AMERICA HEALTH SCREENING MARKET, BY SAMPLE COLLECTION SITES, 2019-2028 (USD MILLION)
TABLE 68 NORTH AMERICA HOSPITAL IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 69 NORTH AMERICA HOSPITAL IN HEALTH SCREENING MARKET, BY SAMPLE COLLECTION SITES, 2019-2028 (USD MILLION)
TABLE 70 NORTH AMERICA HOME IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 71 NORTH AMERICA DIAGNOSTIC LABORATORIES IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 72 NORTH AMERICA OFFICES IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 73 NORTH AMERICA OTHERS IN HEALTH SCREENING MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 74 NORTH AMERICA HEALTH SCREENING MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 75 NORTH AMERICA HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 76 NORTH AMERICA CHOLESTEROL TESTS IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 77 NORTH AMERICA DIABETES TEST IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 78 NORTH AMERICA CANCER SCREENING IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 79 NORTH AMERICA GENERAL CHECK UP TEST IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 80 NORTH AMERICA REGULAR CHECK UP IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 81 NORTH AMERICA STD'S IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 82 NORTH AMERICA OTHER TEST IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 83 NORTH AMERICA HEALTH SCREENING MARKET, BY PACKAGE TYPE, 2019-2028 (USD MILLION)
TABLE 84 NORTH AMERICA HEALTH SCREENING MARKET, BY PANEL TYPE, 2019-2028 (USD MILLION)
TABLE 85 NORTH AMERICA SINGLE-TEST PANELS IN HEALTH SCREENING MARKET, BY PANEL TYPE, 2019-2028 (USD MILLION)
TABLE 86 NORTH AMERICA HEALTH SCREENING MARKET, BY SAMPLE TYPES, 2019-2028 (USD MILLION)
TABLE 87 NORTH AMERICA HEALTH SCREENING MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 88 NORTH AMERICA QPCR IN HEALTH SCREENING MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 89 NORTH AMERICA Q-FISH (QUANTITATIVE FLUORESCENCE IN SITU HYBRIDIZATION) IN HEALTH SCREENING MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 90 NORTH AMERICA HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 91 NORTH AMERICA CARDIOVASCULAR DISEASE IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 92 NORTH AMERICA METABOLIC DISORDERS IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 93 NORTH AMERICA INFLAMMATORY CONDITIONS IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 94 NORTH AMERICA MUSCULOSKELETAL DISORDERS IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 95 NORTH AMERICA NEUROLOGICAL CONDITIONS IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 96 NORTH AMERICA HEALTH SCREENING MARKET, BY SAMPLE COLLECTION SITES, 2019-2028 (USD MILLION)
TABLE 97 NORTH AMERICA HOSPITALS IN HEALTH SCREENING MARKET, BY SAMPLE COLLECTION SITES, 2019-2028 (USD MILLION)
TABLE 98 NORTH AMERICA HEALTH SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 99 U.S. HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 100 U.S. CHOLESTEROL TESTS IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 101 U.S. DIABETES TEST IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 102 U.S. CANCER SCREENING IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 103 U.S. GENERAL CHECK UP TEST IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 104 U.S. REGULAR CHECK UP IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 105 U.S. STD'S IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 106 U.S. OTHER TEST IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 107 U.S. HEALTH SCREENING MARKET, BY PACKAGE TYPE, 2019-2028 (USD MILLION)
TABLE 108 U.S. HEALTH SCREENING MARKET, BY PANEL TYPE, 2019-2028 (USD MILLION)
TABLE 109 U.S. SINGLE-TEST PANELS IN HEALTH SCREENING MARKET, BY PANEL TYPE, 2019-2028 (USD MILLION)
TABLE 110 U.S. HEALTH SCREENING MARKET, BY SAMPLE TYPES, 2019-2028 (USD MILLION)
TABLE 111 U.S. HEALTH SCREENING MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 112 U.S. QPCR IN HEALTH SCREENING MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 113 U.S. Q-FISH (QUANTITATIVE FLUORESCENCE IN SITU HYBRIDIZATION) IN HEALTH SCREENING MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 114 U.S. HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 115 U.S. CARDIOVASCULAR DISEASE IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 116 U.S. METABOLIC DISORDERS IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 117 U.S. INFLAMMATORY CONDITIONS IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 118 U.S. MUSCULOSKELETAL DISORDERS IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 119 U.S. NEUROLOGICAL CONDITIONS IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 120 U.S. HEALTH SCREENING MARKET, BY SAMPLE COLLECTION SITES, 2019-2028 (USD MILLION)
TABLE 121 U.S. HOSPITALS IN HEALTH SCREENING MARKET, BY SAMPLE COLLECTION SITES, 2019-2028 (USD MILLION)
TABLE 122 U.S. HEALTH SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 123 CANADA HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 124 CANADA CHOLESTEROL TESTS IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 125 CANADA DIABETES TEST IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 126 CANADA CANCER SCREENING IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 127 CANADA GENERAL CHECK UP TEST IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 128 CANADA REGULAR CHECK UP IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 129 CANADA STD'S IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 130 CANADA OTHER TEST IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 131 CANADA HEALTH SCREENING MARKET, BY PACKAGE TYPE, 2019-2028 (USD MILLION)
TABLE 132 CANADA HEALTH SCREENING MARKET, BY PANEL TYPE, 2019-2028 (USD MILLION)
TABLE 133 CANADA SINGLE-TEST PANELS IN HEALTH SCREENING MARKET, BY PANEL TYPE, 2019-2028 (USD MILLION)
TABLE 134 CANADA HEALTH SCREENING MARKET, BY SAMPLE TYPES, 2019-2028 (USD MILLION)
TABLE 135 CANADA HEALTH SCREENING MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 136 CANADA QPCR IN HEALTH SCREENING MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 137 CANADA Q-FISH (QUANTITATIVE FLUORESCENCE IN SITU HYBRIDIZATION) IN HEALTH SCREENING MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 138 CANADA HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 139 CANADA CARDIOVASCULAR DISEASE IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 140 CANADA METABOLIC DISORDERS IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 141 CANADA INFLAMMATORY CONDITIONS IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 142 CANADA MUSCULOSKELETAL DISORDERS IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 143 CANADA NEUROLOGICAL CONDITIONS IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 144 CANADA HEALTH SCREENING MARKET, BY SAMPLE COLLECTION SITES, 2019-2028 (USD MILLION)
TABLE 145 CANADA HOSPITALS IN HEALTH SCREENING MARKET, BY SAMPLE COLLECTION SITES, 2019-2028 (USD MILLION)
TABLE 146 CANADA HEALTH SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 147 MEXICO HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 148 MEXICO CHOLESTEROL TESTS IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 149 MEXICO DIABETES TEST IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 150 MEXICO CANCER SCREENING IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 151 MEXICO GENERAL CHECK UP TEST IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 152 MEXICO REGULAR CHECK UP IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 153 MEXICO STD'S IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 154 MEXICO OTHER TEST IN HEALTH SCREENING MARKET, BY TEST TYPE, 2019-2028 (USD MILLION)
TABLE 155 MEXICO HEALTH SCREENING MARKET, BY PACKAGE TYPE, 2019-2028 (USD MILLION)
TABLE 156 MEXICO HEALTH SCREENING MARKET, BY PANEL TYPE, 2019-2028 (USD MILLION)
TABLE 157 MEXICO SINGLE-TEST PANELS IN HEALTH SCREENING MARKET, BY PANEL TYPE, 2019-2028 (USD MILLION)
TABLE 158 MEXICO HEALTH SCREENING MARKET, BY SAMPLE TYPES, 2019-2028 (USD MILLION)
TABLE 159 MEXICO HEALTH SCREENING MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 160 MEXICO QPCR IN HEALTH SCREENING MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 161 MEXICO Q-FISH (QUANTITATIVE FLUORESCENCE IN SITU HYBRIDIZATION) IN HEALTH SCREENING MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 162 MEXICO HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 163 MEXICO CARDIOVASCULAR DISEASE IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 164 MEXICO METABOLIC DISORDERS IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 165 MEXICO INFLAMMATORY CONDITIONS IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 166 MEXICO MUSCULOSKELETAL DISORDERS IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 167 MEXICO NEUROLOGICAL CONDITIONS IN HEALTH SCREENING MARKET, BY CONDITION, 2019-2028 (USD MILLION)
TABLE 168 MEXICO HEALTH SCREENING MARKET, BY SAMPLE COLLECTION SITES, 2019-2028 (USD MILLION)
TABLE 169 MEXICO HOSPITALS IN HEALTH SCREENING MARKET, BY SAMPLE COLLECTION SITES, 2019-2028 (USD MILLION)
TABLE 170 MEXICO HEALTH SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
Liste des figures
FIGURE 1 NORTH AMERICA HEALTH SCREENING MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA HEALTH SCREENING MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA HEALTH SCREENING MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA HEALTH SCREENING MARKET : NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA HEALTH SCREENING MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA HEALTH SCREENING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA HEALTH SCREENING MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA HEALTH SCREENING MARKET: MARKET DISTRIBUTION CHANNEL COVERAGE GRID
FIGURE 9 NORTH AMERICA HEALTH SCREENING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA HEALTH SCREENING MARKET: SEGMENTATION
FIGURE 11 HIGH PREVALENCE OF CHRONIC DISEASES IS EXPECTED TO DRIVE THE NORTH AMERICA HEALTH SCREENING MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 CHOLESTROL TESTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA HEALTH SCREENING MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA HEALTH SCREENING MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA HEALTH SCREENING MARKET
FIGURE 15 PREVALENCE OF CHRONIC DISEASES
FIGURE 16 AGING POPULATION IN THE WORLD (IN MILLION)
FIGURE 17 NORTH AMERICA AGING POPULATION (IN MILLION)
FIGURE 18 EUROPE AGING POPULATION (IN MILLION)
FIGURE 19 ASIA-PACIFIC AGING POPULATION (IN MILLION)
FIGURE 20 NORTH AMERICA HEALTH SCREENING MARKET: BY TEST TYPE, 2020
FIGURE 21 NORTH AMERICA HEALTH SCREENING MARKET: BY TEST TYPE, 2021-2028 (USD MILLION)
FIGURE 22 NORTH AMERICA HEALTH SCREENING MARKET: BY TEST TYPE, CAGR (2021-2028)
FIGURE 23 NORTH AMERICA HEALTH SCREENING MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 24 NORTH AMERICA HEALTH SCREENING MARKET: BY PANEL TYPE, 2020
FIGURE 25 NORTH AMERICA HEALTH SCREENING MARKET: BY PANEL TYPE, 2021-2028 (USD MILLION)
FIGURE 26 NORTH AMERICA HEALTH SCREENING MARKET: BY PANEL TYPE, CAGR (2021-2028)
FIGURE 27 NORTH AMERICA HEALTH SCREENING MARKET: BY PANEL TYPE, LIFELINE CURVE
FIGURE 28 NORTH AMERICA HEALTH SCREENING MARKET: BY PACKAGE TYPE, 2020
FIGURE 29 NORTH AMERICA HEALTH SCREENING MARKET: BY PACKAGE TYPE, 2021-2028 (USD MILLION)
FIGURE 30 NORTH AMERICA HEALTH SCREENING MARKET: BY PACKAGE TYPE, CAGR (2021-2028)
FIGURE 31 NORTH AMERICA HEALTH SCREENING MARKET: BY PACKAGE TYPE, LIFELINE CURVE
FIGURE 32 NORTH AMERICA HEALTH SCREENING MARKET: BY SAMPLE TYPE, 2020
FIGURE 33 NORTH AMERICA HEALTH SCREENING MARKET: BY SAMPLE TYPE, 2021-2028 (USD MILLION)
FIGURE 34 NORTH AMERICA HEALTH SCREENING MARKET: BY SAMPLE TYPE, CAGR (2021-2028)
FIGURE 35 NORTH AMERICA HEALTH SCREENING MARKET: BY SAMPLE TYPE, LIFELINE CURVE
FIGURE 36 NORTH AMERICA HEALTH SCREENING MARKET: BY TECHNOLOGY, 2020
FIGURE 37 NORTH AMERICA HEALTH SCREENING MARKET: BY TECHNOLOGY, 2021-2028 (USD MILLION)
FIGURE 38 NORTH AMERICA HEALTH SCREENING MARKET: BY TECHNOLOGY, CAGR (2021-2028)
FIGURE 39 NORTH AMERICA HEALTH SCREENING MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 40 NORTH AMERICA HEALTH SCREENING MARKET: BY CONDITION, 2020
FIGURE 41 NORTH AMERICA HEALTH SCREENING MARKET: BY CONDITION, 2021-2028 (USD MILLION)
FIGURE 42 NORTH AMERICA HEALTH SCREENING MARKET: BY CONDITION, CAGR (2021-2028)
FIGURE 43 NORTH AMERICA HEALTH SCREENING MARKET: BY CONDITION, LIFELINE CURVE
FIGURE 44 NORTH AMERICA HEALTH SCREENING MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 45 NORTH AMERICA HEALTH SCREENING MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 46 NORTH AMERICA HEALTH SCREENING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 47 NORTH AMERICA HEALTH SCREENING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 48 NORTH AMERICA HEALTH SCREENING MARKET: BY SAMPLE COLLECTION SITES, 2020
FIGURE 49 NORTH AMERICA HEALTH SCREENING MARKET: BY SAMPLE COLLECTION SITES, 2021-2028 (USD MILLION)
FIGURE 50 NORTH AMERICA HEALTH SCREENING MARKET: BY SAMPLE COLLECTION SITES, CAGR (2021-2028)
FIGURE 51 NORTH AMERICA HEALTH SCREENING MARKET: BY SAMPLE COLLECTION SITES, LIFELINE CURVE
FIGURE 52 NORTH AMERICA HEALTH SCREENING MARKET: SNAPSHOT (2020)
FIGURE 53 NORTH AMERICA HEALTH SCREENING MARKET: BY COUNTRY (2020)
FIGURE 54 NORTH AMERICA HEALTH SCREENING MARKET: BY COUNTRY (2021 & 2028)
FIGURE 55 NORTH AMERICA HEALTH SCREENING MARKET: BY COUNTRY (2020 & 2028)
FIGURE 56 NORTH AMERICA HEALTH SCREENING MARKET: BY TEST TYPE (2021-2028)
FIGURE 57 NORTH AMERICA HEALTH SCREENING MARKET: COMPANY SHARE 2020(%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
